Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development

Clicks: 325
ID: 114532
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #85 of 253 articles by views in journal of clinical medicine

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 253 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Antisense oligonucleotides (ASOs) bind sequence specifically to the target RNA and modulate protein expression through several different mechanisms. The ASO field is an emerging area of drug development that targets the disease source at the RNA level and offers a promising alternative to therapies targeting downstream processes. To translate ASO-based therapies into a clinical success, it is crucial to overcome the challenges associated with off-target side effects and insufficient biological activity. In this regard, several chemical modifications and diverse delivery strategies have been explored. In this review, we systematically discuss the chemical modifications, mechanism of action, and optimized delivery strategies of several different classes of ASOs. Further, we highlight the recent advances made in development of ASO-based drugs with a focus on drugs that are approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for clinical applications. We also discuss various promising ASO-based drug candidates in the clinical trials, and the outstanding opportunity of emerging microRNA as a viable therapeutic target for future ASO-based therapies.
Reference Key
dhuri2020journalantisense Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Karishma Dhuri;Clara Bechtold;Elias Quijano;Ha Pham;Anisha Gupta;Ajit Vikram;Raman Bahal;Dhuri, Karishma;Bechtold, Clara;Quijano, Elias;Pham, Ha;Gupta, Anisha;Vikram, Ajit;Bahal, Raman;
Journal journal of clinical medicine
Year 2020
DOI
10.3390/jcm9062004
URL
https://doi.org/10.3390/jcm9062004
Keywords
clinical trials rna antisense oligonucleotides chemical modifications

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.